Ā 

AMAG shares rise on strong revenue outlook for anemia drug - Reuters PDF Print
Reuters"We expect long-term Feraheme growth to be driven by the non-dialysis setting, which offers a faster sales cycle and no exposure to the pending bundled ...AMAG Pharmaceuticals Announces Preliminary FerahemeĀ® Fourth Quarter 2009 Net

... read more

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.